Biotrin: Zeroing in on organ damage

Emerging Company Profile

Biotrin Holdings Ltd. operated for its first year and a half without venture money, which meant it needed products in order to survive. Now with $2.5 million in sales in 1995 from the sale of test kits for the virology and transplant markets, the Dublin, Ireland, company is focused on creating a franchise in biomarkers that can rapidly and specifically detect damage and treatment effects in transplanted organs...